Stocks and Investing
Stocks and Investing
Wed, May 8, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Gena Wang Maintained (BEAM) at Hold with Decreased Target to $33 on, May 8th, 2024
Gena Wang of Barclays, Maintained "Beam Therapeutics Inc." (BEAM) at Hold with Decreased Target from $42 to $33 on, May 8th, 2024.
Gena has made no other calls on BEAM in the last 4 months.
There are 4 other peers that have a rating on BEAM. Out of the 4 peers that are also analyzing BEAM, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $35 on, Wednesday, February 28th, 2024
These are the ratings of the 3 analyists that currently disagree with Gena
- David Nierengarten of "Wedbush" Reiterated at Buy and Held Target at $57 on, Tuesday, April 23rd, 2024
- Kostas Biliouris of "BMO Capital" Maintained at Buy and Held Target at $57 on, Wednesday, March 27th, 2024
- Eric Joseph of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $40 on, Monday, January 29th, 2024
Contributing Sources